Next Article in Journal
Hepatoprotective Role of Carvedilol against Ischemic Hepatitis Associated with Acute Heart Failure via Targeting miRNA-17 and Mitochondrial Dynamics-Related Proteins: An In Vivo and In Silico Study
Next Article in Special Issue
Search for Novel Potent Inhibitors of the SARS-CoV-2 Papain-like Enzyme: A Computational Biochemistry Approach
Previous Article in Journal
Pentagalloyl Glucose and Cisplatin Combination Treatment Exhibits a Synergistic Anticancer Effect in 2D and 3D Models of Head and Neck Carcinoma
Previous Article in Special Issue
The Potential Complementary Role of Using Chinese Herbal Medicine with Western Medicine in Treating COVID-19 Patients: Pharmacology Network Analysis
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 15
Issue 7
10.3390/ph15070831
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Optimization of 2-Aminoquinazolin-4-(3H)-one Derivatives as Potent Inhibitors of SARS-CoV-2: Improved Synthesis and Pharmacokinetic Properties

by
Young Sup Shin
1,2,†,
Jun Young Lee
1,2,†,
Sangeun Jeon
3,
Jung-Eun Cho
2,
Subeen Myung
2,4,
Min Seong Jang
5,
Seungtaek Kim
3,
Jong Hwan Song
2,
Hyoung Rae Kim
2,
Hyeung-geun Park
1,*,
Lak Shin Jeong
1,* and
Chul Min Park
2,4,*
1
Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 08826, Korea
2
Center for Convergent Research of Emerging Virus Infection (CEVI), Korea Research Institute of Chemical Technology, 141 Gajeong-ro, Yuseong-gu, Daejeon 34114, Korea
3
Zoonotic Virus Laboratory, Institut Pasteur Korea, Gyeonggi, Seongnam 13488, Korea
4
Medicinal Chemistry and Pharmacology, Korea University of Science and Technology, Daejeon 34114, Korea
5
Department of Non-Clinical Studies, Korea Institute of Toxicology, Yuseong-gu, Daejeon 34114, Korea
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Pharmaceuticals 2022, 15(7), 831; https://doi.org/10.3390/ph15070831
Submission received: 12 May 2022 / Revised: 29 June 2022 / Accepted: 30 June 2022 / Published: 4 July 2022
(This article belongs to the Special Issue COVID-19 in Pharmaceuticals)
Browse Figures
Review Reports Versions Notes

Abstract

:
We previously reported the potent antiviral effect of the 2-aminoquinazolin-4-(3H)-one 1, which shows significant activity (IC50 = 0.23 μM) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with no cytotoxicity. However, it is necessary to improve the in vivo pharmacokinetics of compound 1 because its area under the curve (AUC) and maximum plasma concentration are low. Here, we designed and synthesized N-substituted quinazolinone derivatives that had good pharmacokinetics and that retained their inhibitory activity against SARS-CoV-2. These compounds were conveniently prepared on a large scale through a one-pot reaction using Dimroth rearrangement as a key step. The synthesized compounds showed potent inhibitory activity, low binding to hERG channels, and good microsomal stability. In vivo pharmacokinetic studies showed that compound 2b had the highest exposure (AUC24h = 41.57 μg∙h/mL) of the synthesized compounds. An in vivo single-dose toxicity evaluation of compound 2b at 250 and 500 mg/kg in rats resulted in no deaths and an approximate lethal dose greater than 500 mg/kg. This study shows that N-acetyl 2-aminoquinazolin-4-(3H)-one 2b is a promising lead compound for developing anti-SARS-CoV-2 agents.

1. Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread rapidly, caused the coronavirus disease 2019 (COVID-19) pandemic, and severely threatened global healthcare systems [1,2,3]. Since its first appearance in December 2019 in Wuhan, China, there have been over 533 million confirmed cases of COVID-19 worldwide as well as over 6.3 million deaths by 15 June 2022 [4].
SARS-CoV-2, which is an enveloped, positive-sense, single-stranded RNA beta-coronavirus, is one of seven coronaviruses known to infect humans. SARS-CoV, MERS-CoV, and SARS-CoV-2 cause severe acute respiratory tract infections, whereas HCoV-229E, HCoV-NL63, HCoV-OC43, and HCoV-HKU1 cause mild symptoms [5]. The genome sequence of SARS-CoV-2 is closely related to the sequence of SARS-like bat coronaviruses (bat-SL-CoVZC45 and bat-SL-CoVZXC21), sharing 88% identity, but has less genetic similarity to SARS-CoV (about 79%) and MERS-CoV (about 50%) [6].
Despite the effective COVID-19 vaccines that were developed at an unprecedented pace, SARS-CoV-2 variants, which spread more easily, continue to appear [7]. The transmission of the Delta variant, a lineage first detected in India in December 2020, is higher than that of the Alpha variant, which itself is more contagious than the original virus [8]. The Omicron variant, first discovered in South Africa in November 2021, is more infectious than the Delta variant and is more likely to lead to breakthrough infection in vaccinated individuals [9].
During the current COVID-19 pandemic, drug repurposing is the quickest way to find effective treatments, given that the safety profiles of repurposed drugs are generally well-established [10]. Several candidates have been investigated in large randomized clinical trials since early 2020. Although many drug candidates are being developed against COVID-19, there is currently no established treatment. Hydroxychloroquine and lopinavir–ritonavir, which received attention at the beginning of the pandemic, did not show good efficacy in clinical trials [11,12]. Remdesivir, which received emergency use approval from the US FDA, can be administered via IV to hospitalized patients and shortens recovery time but does not reduce mortality [13]. Molnupiravir, a prodrug of the nucleoside derivative N4-hydroxycytidine, is an orally available broad-spectrum antiviral agent that received emergency use approval by the US FDA in December 2021. However, results from phase 3 of the MOVe-OUT trial showed that the drug had modest effects. The primary outcome, the incidence of hospitalization or death at day 29, was 6.8% (48 out of 709 patients) in the molnupiravir group and 9.7% (68 out of 699 patients) in the placebo group, representing a 30% reduction in COVID-19-related hospitalization or death [14,15]. The potential for molnupiravir-induced mutagenesis remains a concern because its mechanism causes the accumulation of errors during RNA synthesis [16,17,18,19]. Additionally, in December 2021, the US FDA issued emergency use authorization for Paxlovid (two tablets of nirmatrelvir and one tablet of ritonavir). In the final analysis of the primary endpoint in the EPIC-HR phase 3 study, 0.7% of patients (5/697 hospitalized with no deaths) in the Paxlovid group were hospitalized, and 6.5% of patients (44/682 hospitalized with nine subsequent deaths) in the placebo group were hospitalized or died. Paxlovid reduced COVID-19-related hospitalization or death by 89%. [20]. It remains to be seen whether Paxlovid will be a game-changer given the potential for drug resistance or drug interactions. Therefore, in the absence of an agent with clear therapeutic benefits, new antiviral treatments for COVID-19 are still needed.
We recently reported that 2-aminoquinazolin-4-(3H)-one 1 has potent antiviral effects against SARS-CoV-2 and MERS-CoV [21,22]. Compound 1 showed significant activity (IC50 = 0.23 μM) against SARS-CoV-2 in a Vero cell assay, with no cytotoxicity and promising in vitro pharmacokinetic properties, including high microsomal stability and low binding to hERG channels.
However, it is necessary to improve the in vivo pharmacokinetics of compound 1 because its area under the curve (AUC) and maximum plasma concentration (Cmax) are low. These poor pharmacokinetic properties may be attributed to its planar structure. Therefore, our strategy in this study was to design N-substituted quinazolinone derivatives with good pharmacokinetics that retain their inhibitory activity against SARS-CoV-2 (Figure 1). Moreover, we attempted to conveniently synthesize aminoquinazolin-4-(3H)-one derivatives on a large scale. Here, we report the efficient synthesis of aminoquinazolin-4-(3H)-one derivatives and an assessment of the in vivo pharmacokinetics of an N-acetylated compound in rats.

2. Results and Discussion

2.1. Synthesis of 2-Aminoquinazolin-4-(3H)-one Derivatives

In the synthetic route used in our previous study, four steps were performed to synthesize key intermediate 1 with an overall yield of 50% [21,22]. The second step, which used an excess of POCl3, made the synthesis difficult because the product was unstable and easily returned to the starting material. For efficient and bulk synthesis, we used the one-pot reaction method of Tun-Cheng Chien’s group to synthesize intermediate 1 with an overall yield of 76% (Scheme 1) [23]. Anthranilic acid 3 was treated with phenylcyanamide 4 and chlorotrimethylsilane to yield a mixture of 2-(N-substituted-amino)quinazolin-4-one 1 and 3-substituted 2-aminoquinazolin-4-one. A Dimroth rearrangement with 2 N sodium hydroxide in EtOH/H2O (1/1) afforded the key intermediate 1 [24]. This one-pot reaction, which was not sensitive to moisture, generated a large amount of the pure product 1 without the use of column chromatography. Demethylation of 1c with boron tribromide afforded 5c. Acetylation of 1a, 1b, and 5c with acetic anhydride and triethylamine yielded N-acetylated compounds 2a, 2b, and 2c, respectively. 1a was treated with propionyl chloride, methyl chloroformate, iodomethane or p-toluenesulfonyl chloride, and triethylamine to yield the corresponding 6. Compound 7 was also prepared by reacting compound 1a and benzyloxyacetyl chloride with triethylamine. The hydrogenation of 7 in the presence of 10% Pd/C yielded alcohol 8.

2.2. In Vitro Activity against SARS-CoV-2

The synthesized compounds were evaluated for antiviral activity against SARS-CoV-2. The nucleotide analog remdesivir was used as a reference compound (Table 1). The activity of the compounds was tested by immunofluorescence assay in Vero cells at 10 concentrations, starting at 25 μM in two-fold serial dilutions to determine the IC50 values [25]. Cytotoxicity (the CC50 value) was determined in parallel in uninfected cells. As shown in Table 1, acetylated derivatives 2a, 2b, and 2c had potent inhibitory activity against SARS-CoV-2 (IC50 = 0.33, 0.29, and 0.11 μM, respectively). In addition, the acetylated compounds had lower ClogP values than compound 1a, so it was expected that the pharmacokinetic properties would be improved. The propionyl 6a and p-tosyl 6d showed good activity (IC50 = 0.21 and 0.57 μM, respectively) but had ClogP values of 5.1 and 6.5, respectively, which lowered their priority for further investigation. The methyl carbamate 6b, methyl 6c, and hydroxyacetyl 8 showed only marginal antiviral activity (IC50 = 7.05, 5.66, and 2.57 μM, respectively).

2.3. Mode of Action Study

The anti-SARS-CoV-2 activity of quinazolinones has been frequently reported upon, but the mode of action is still unidentified. Several promising targets for COVID-19 therapeutics have been reported, including angiotensin-converting Enzyme 2 (ACE-2), transmembrane protease serine subtype 2 (TMPRSS2), RNA-dependent RNA polymerase (RdRp), and 3-chymotrypsin-like protease (3CLpro) [3]. Among these targets, we focused on those involved in the viral entry mechanism.
To assess the effects of the compounds on viral entry, the SARS-CoV-2 spike pseudo-typed lentivirus system was used [26]. We tested the acetylated derivatives 2a and 2b, which showed good activity (IC50 = 0.54 and 0.99 μM, respectively) (Figure S1). The compounds inhibited the entry of the SARS-CoV-2 spike pseudo-typed virus in a concentration-dependent manner, which suggests that the compounds act as entry inhibitors.

2.4. Pharmacokinetics

Compounds 2a–c were selected for in vivo pharmacokinetic studies based on their ClogP and selectivity index (SI) values. Each compound was administered orally at 10 mg/kg to three Sprague Dawley rats (Figure 2). The previously reported pharmacokinetic properties of compound 1a in the rats showed a very low Cmax value of 0.87 μg/mL and an AUC24h of 6.62 μg∙h/mL. Compound 2a had significantly higher exposure than compound 1, with a Cmax value of 1.85 μg/mL and an AUC24h of 24.31 μg∙h/mL. Compound 2c had an AUC24h of only 10.77 μg∙h/mL, which was slightly better than that of compound 1a. We anticipated that compound 2c would have good absorption properties due to its low ClogP value; however, the experimental results showed that compound 2c had lower exposure than compound 2b. This result may be due to the poor solubility of compound 2c. The pharmacokinetic results of compound 2b, which was substituted with a difluoro moiety, showed that it had sufficient exposure, with a Cmax value of 5.56 μg/mL and an AUC24h of 41.57 μg∙h/mL and a blood concentration value that sufficiently exceeded the IC50 value within at least 8 h. The lipophilic properties and the small size of the fluorine moieties likely enhance the absorption of compound 2b.

2.5. hERG Affinity, Microsomal Stability, and Cytotoxicity

Three acetylated compounds 2a-c with strong activity against SARS-CoV-2 and good pharmacokinetic properties were assessed for hERG binding, microsomal stability, and cytotoxicity (Table 2). The results of the hERG patch–clamp assay showed that compounds 2a and 2b had weak activity against the hERG ion channel (IC50 = 15.2 and 30.0 μM, respectively). Compound 2c was devoid of hERG activity (IC50 > 50 μM). Furthermore, the metabolic stability of each compound was determined by evaluating how much the compound remained in the liver microsomes after a 30 min activation of the metabolic enzyme system by NADPH. Compounds 2a and 2b had high stability in rat and human microsomes, whereas only 10% of compound 2c was present in human microsomes at the end of the experiment. The hydroxyl group at position 5 of compound 2c may contribute to this rapid metabolism [27]. Cytotoxicity was evaluated using an EZ-Cytox cell viability assay kit, which uses the water-soluble tetrazolium salt method [28]. Compound 2a showed a CC50 value of less than 10 μM for all four normal cell lines (HFL-1, L929, NIH 3T3, and CHO-K1). Compounds 2b and 2c were relatively free from cytotoxicity. Overall, compound 2b had the best safety and stability profiles in vitro.

2.6. In Vivo Single-Dose Toxicity

Given the potent activity of compound 2b with no cytotoxicity and its promising pharmacokinetic profile, the acute toxicity of this compound was studied in male Sprague Dawley rats at two oral doses: 250 and 500 mg/kg (Figure 3). After single administration using 55% PEG200 in distilled water as a vehicle, each group of four rats was monitored for 15 days. The results of this single-dose toxicity study showed that there was no mortality in the treated or control rats. Observations of clinical signs showed that one animal in the 250 mg/kg group and two animals in the 500 mg/kg group had liquid feces but recovered by day 4. In addition, there was a statistically significant reduction (Dunnett’s test) in body weight on day 4 in the 250 mg/kg group and on days 4 and 8 in the 500 mg/kg group, but both groups recovered on day 14. Gross observations of the organs did not reveal changes in any of the organs examined. Therefore, the approximate lethal dose of compound 2b in this study was estimated to be more than 500 mg/kg.

3. Materials and Methods

3.1. Chemistry

All of the reagents used in the experiments were purchased from commercial suppliers such as Aldrich, Tokyo Chemical Industry, Alfa aesar, or Combi-Blocks and used without further purification. Organic solvents were concentrated under reduced pressure using a Büchi rotary evaporator.
The progress of the reaction was confirmed by thin-layer chromatohgraphy (TLC) using plates coated with Kieselgel 60F254 (Merck), and column chromatography was carried out using RediSep Rf normal-phase silica flash columns (230–400 mesh).
Proton (1H) and carbon (13C) NMR spectra of the compounds were measured using a Bruker with each 300, 400, and 500 instrument at each 300, 400, and 500 MHz interval. Chemical shifts are reported as parts per million (δ) relative to the solvent peak. Resonance patterns are reported with the notations s (singlet), d (doublet), t (triplet), q (quartet), dd (doublet of doublets), and m (multiplet). Coupling constants (J) are reported in hertz. High-resolution mass spectra (HRMS) were obtained from the Korea Research Institute of Chemcial Technology using the FAB ionization method. Melting points were determined on a Metter Toledo MP50 instrument and are uncorrected.

3.1.1. 7-Chloro-2-((3,5-dichlorophenyl)amino)quinazolin-4(3H)-one (1a)

Chlorotrimethylsilane (22 mL, 175 mmol) was added to a stirred suspension of 3a (20 g, 117 mmol) and N-(3,5-dichlorophenyl)cyanamide 4a (32.7 g, 175 mmol) in tert-butanol (300 mL) at rt. The reaction mixture was stirred using a mechanical stirrer for 4 h at 60 °C. To the stirred mixture, 2 N aqueous ethanolic NaOH (H2O/EtOH = 1/1, 1 L) was added at rt. The resulting solution was stirred for 6 h at 110 °C. The mixture was cooled to rt and acidified with the addition of acetic acid (114 mL) in an ice bath. The precipitated solid was collected and washed with H2O (200 mL), DCM (200 mL) and methanol (100 mL). The remaining solid was dried under a high vacuum to obtain 1a (24.8 g, 62%) as a white solid: mp > 300 °C; 1H NMR (400 MHz, DMSO-d6) δ 11.24 (s, 1H, NH), 9.14 (s, 1H, NH), 7.97 (d, J = 8.5 Hz, 1H, arom.CH), 7.81 (s, 2H, arom.CH), 7.47 (d, J = 2.0 Hz, 1H, arom.CH), 7.30 (dd, J = 8.4, 2.1 Hz, 1H, arom.CH), 7.25 (t, J = 1.9 Hz, 1H, arom.CH) ppm; 13C NMR (100 MHz, DMSO-d6) δ 161.01 (C=O quinazolinone), 150.55 (C2 quinazolinone), 148.00 (C8a quinazolinone), 141.17 (C1 aniline), 139.18 (C7 quinazolinone), 134.05 (C5 quinazolinone), 127.89 (C3,5 aniline), 123.84 (C6 quinazolinone), 121.78 (C8 quinazolinone), 117.68 (C4 aniline), 114.68 (C4a quinazolinone), 113.33 (C2,6 aniline) ppm; HRMS (FAB) calculated for [C14H8Cl3N3O]+ ([M]+): 338.9733, observed: 339.9813 m/z [M + H]+.

3.1.2. 7-Chloro-2-((3,5-difluorophenyl)amino)quinazolin-4(3H)-one (1b)

Following the same procedure used for the synthesis of 1a, 3a (4.8 g, 28 mmol), N-(3,5-difluorophenyl)cyanamide 4b (6.5 g, 42 mmol) and chlorotrimethylsilane (5 mL, 42 mmol) were used to obtain 1b (5 g, 58%) as a white solid: mp > 300 °C; 1H NMR (500 MHz, DMSO-d6) δ 11.08 (s, 1H, NH), 9.13 (s, 1H, NH), 7.94 (d, J = 8.4 Hz, 1H, arom.CH), 7.53–7.42 (m, 3H, arom.CH), 7.26 (dd, J = 8.4, 2.1 Hz, 1H, arom.CH), 6.85 (tt, J = 9.2, 2.4 Hz, 1H, arom.CH) ppm; 13C NMR (125 MHz, DMSO-d6) δ 163.47 (d, J = 15.7 Hz, C3 aniline), 161.54 (d, J = 15.5 Hz, C5 aniline), 160.98 (C=O quinazolinone), 150.61 (C2 quinazolinone), 147.95 (C8a quinazolinone), 141.33 (t, J = 14.0 Hz, C1 aniline), 139.19 (C7 quinazolinone), 127.84 (C5 quinazolinone), 124.67 (C6 quinazolinone), 123.83 (C8 quinazolinone), 117.45 (C4a quinazolinone), 102.28 (d, J = 29.1 Hz, C2,6 aniline), 97.61 (t, J = 26.2 Hz, C4 anline) ppm; HRMS (FAB) calculated for [C14H8ClF2N3O]+ ([M]+): 307.0324, observed: 307.0323 m/z [M]+.

3.1.3. 2-((3,5-Dichlorophenyl)amino)-5-methoxyquinazolin-4(3H)-one (1c)

Following the same procedure used for the synthesis of 1a, 3b (20 g, 131 mmol), N-(3,5-dichlorophenyl)-cyanamide 4a (36.6 g, 196 mmol) and chlorotrimethylsilane (25 mL, 196 mmol) were used to obtain 1c (9.6 g, 24%) as a white solid: mp > 300 °C; 1H NMR (500 MHz, DMSO-d6) δ 10.74 (s, 1H, NH), 8.91 (s, 1H, NH), 7.81 (s, 2H, arom.CH), 7.55 (t, J = 8.2 Hz, 1H, arom.CH), 7.20 (s, 1H, arom.CH), 6.95 (d, J = 8.1 Hz, 1H, arom.CH), 6.79 (d, J = 8.3 Hz, 1H, arom.CH), 3.82 (s, 3H, OCH3) ppm; 13C NMR (125 MHz, DMSO-d6) δ 160.02 (C=O quinazolinone), 159.68 (C5 quinazolinone), 151.68 (C2 quinazolinone), 151.87 (C8a quinazolinone), 147.22 (C1 aniline), 141.56 (C7 quinazolinone), 134.88 (C3,5 anilne), 134.05 (C8 quinazolinone), 121.35 (C4 aniline), 117.47 (d, J = 50.1 Hz, C2,6 anilne), 108.33 (C6 quinazolinone), 105.76 (C4a quinazolinone), 55.81 (OCH3) ppm; HRMS (FAB) calculated for [C14H9Cl2N3O2]+ ([M]+): 321.0072, observed: 321.0058 m/z [M]+.

3.1.4. N-(3,5-Dichlorophenyl)cyanamide (4a)

Cyanogen bromide (39 g, 370 mmol) and 1N NaOH (340 mL) were added to a stirred suspension of 3,5-dichloroaniline (50 g, 309 mmol) in acetic acid (150 mL) and water (1050 mL) at rt. The reaction mixture was stirred for 18 h at rt. The solid was filtered and washed with water (400 mL) and hexane (200 mL). The remaining solid was dried under a high vacuum to obtain 4a (55.7 g, 97%) as a white solid: mp 182–184 °C; 1H NMR (400 MHz, DMSO-d6) δ 10.78 (s, 1H, NH), 7.27 (t, J = 1.8 Hz, 1H, arom.CH), 6.93 (d, J = 1.8 Hz, 2H, arom.CH) ppm; 13C NMR (100 MHz, DMSO-d6) δ 141.59 (C1 aniline), 135.16 (C3,5 aniline), 122.10 (CN), 113.77 (C4 aniline), 110.77 (C2,6 aniline) ppm; HRMS (FAB) calculated for [C7H4Cl2N2]+ ([M]+): 185.9752, observed: 185.9751 m/z [M]+.

3.1.5. N-(3,5-Dichlorophenyl)cyanamide (4b)

Following the same procedure used for the synthesis of 4a, 3,5-difluoroaniline (20 g, 155 mmol) and cyanogen bromide (20 g, 186 mmol) were used to obtain 4b (23 g, 96%) as a white solid; mp 134–136 °C; 1H NMR (400 MHz, DMSO-d6) δ 6.91 (tt, J = 9.4, 2.2 Hz, 1H, arom.CH), 6.70–6.57 (m, 2H, arom.CH) ppm; 13C NMR (100 MHz, DMSO-d6) δ 164.20 (d, J = 15.4 Hz, C3 aniline), 162.24 (d, J = 15.5 Hz, C5 aniline), 141.97 (t, J = 13.4 Hz, C1 aniline), 110.88 (CN), 99.14–98.53 (m, C2,6 aniline), 98.01 (t, J = 26.1 Hz, C4 aniline) ppm; HRMS (FAB) calculated for [C7H4F2N2]+ ([M]+): 154.0343, observed: 154.0353 m/z [M]+.

3.1.6. 2-((3,5-Dichlorophenyl)amino)-5-hydroxyquinazolin-4(3H)-one (5c)

To a stirred suspension of 1c (4.5 g, 14.7 mmol) in anhydrous CH2Cl2 (150 mL) was added dropwise BBr3 (1.0 M solution in CH2Cl2, 44 mL, 44 mmol) at –78 °C. The reaction mixture was stirred for 3 h at rt. The mixture was quenched by the dropwise addition of methanol at 0 °C and concentrated under reduced pressure. The solid was filtered and washed with water, hexane, and methanol. The remaining solid was dried under a high vacuum to obtain 5c (4 g, 97%) as a white solid; mp > 300 °C; 1H NMR (300 MHz, DMSO-d6) δ 11.55 (s, 2H, OH, NH), 9.25 (s, 1H, NH), 7.77 (s, 2H, arom.CH), 7.51 (t, J = 8.1 Hz, 1H, arom.CH), 7.26 (s, 1H, arom.CH), 6.83 (d, J = 8.1 Hz, 1H, arom.CH), 6.61 (d, J = 8.1 Hz, 1H, arom.CH) ppm; 13C NMR (125 MHz, DMSO-d6) δ 160.38 (C=O, C-OH quinazolinone), 141.45 (C2 quinazolinone), 136.54 (C8a quinazolinone, C1 aniline), 134.49 (C7 quinazolinone), 122.68 (C8 quinazolinone, C4 aniline), 118.87 (C6 quinazolinone), 109.91 (C2,6 aniline), 104.85 (C4a quinazolinone) ppm; HRMS (FAB) calculated for [C14H9Cl2N3O2]+ ([M]+): 321.0072, observed: 321.0058 m/z [M]+.

3.1.7. N-(7-Dichloro-4-oxo-3,4-dihydroquinazolin-2-yl)-N-(3,5-dichlorophenyl)acetamide (2a)

To a stirred suspension of 1a (5 g, 14.7 mmol) in CH2Cl2 (75 mL) were added trimethylamine (4.1 mL, 29.3 mmol) and acetic anhydride (4.2 mL, 44.0 mmol) at rt. The reaction mixture was stirred for 18 h at 40 °C. After the completion of the reaction (determined by TLC), the mixture was cooled to rt and diluted with CH2Cl2 (75 mL), then the mixture was washed with water (100 mL). The organic phase was concentrated under reduced pressure to obtain a crude solid, which was washed with CH2Cl2 (200 mL) and methanol (100 mL) to obtain 2a (4.2 g, 75%) as a white solid; mp 236–238 °C; 1H NMR (500 MHz, DMSO-d6) δ 12.87 (s, 1H, NH), 8.09 (d, J = 8.4 Hz, 1H, arom.CH), 7.68 (t, J = 1.9 Hz, 1H, arom.CH), 7.62 (d, J = 2.1 Hz, 1H, arom.CH), 7.59 (d, J = 1.9 Hz, 2H, arom.CH), 7.54 (dd, J = 8.5, 2.1 Hz, 1H, arom.CH), 2.13 (s, 3H, CH3) ppm; 13C NMR (125 MHz, DMSO-d6) δ 171.39 (C=O acetyl), 161.92 (C=O quinazolinone), 149.54 (C2 quinazolinone), 149.07 (C8a quinazolinone), 141.62 (C1 aniline), 139.79 (C7 quinazolinone), 134.73 (C2,6 aniline), 128.46 (C5 quinazolinone), 128.45 (C3,5 aniline), 127.56 (C6 quinazolinone), 127.47 (C4 aniline), 126.77 (C8 quinazolinone), 120.18 (C4a quinazolinone), 24.29 (CH3 acetyl) ppm; HRMS (FAB) calculated for [C16H10Cl3N3O2]+ ([M]+): 380.9839, observed: 380.9838 m/z [M]+.

3.1.8. N-(7-Chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-N-(3,5-difluorophenyl)acetamide (2b)

To a stirred suspension of 1b (151 mg, 0.49 mmol) in CH2Cl2 (2.5 mL) were added trimethylamine (137 μL, 0.98 mmol) and acetic anhydride (139 μL, 1.47 mmol) at rt. The reaction mixture was stirred for 5 h at 40 °C. The mixture was cooled to rt and diluted with CH2Cl2 (20 mL), then the mixture was washed with water (20 mL). The organic phase was dried over MgSO4, filtered, and concentrated under reduced pressure to obtain the crude compound, which was purified by silica gel column chromatography (Hx/EA 5/1) to produce 2b (124 mg, 72%) as a white solid; mp 178–180 °C; 1H NMR (700 MHz, acetone-d6) δ 12.45 (s, 1H, NH), 8.08 (d, J = 8.5 Hz, 1H, arom.CH), 7.40 (dd, J = 8.5, 2.0 Hz, 1H, arom.CH), 7.36 (dd, J = 7.3, 2.3 Hz, 2H, arom.CH), 7.29 (d, J = 2.1 Hz, 1H, arom.CH), 7.26 (ddd, J = 9.2, 6.8, 2.4 Hz, 1H, arom.CH), 2.18 (s, 3H, CH3) ppm; 13C NMR (175 MHz, acetone-d6) δ 175.96 (C=O acetyl), 165.45 (d, J = 14.6 Hz, C3 aniline), 164.04 (d, J = 14.2 Hz, C5 aniline), 161.61 (C=O quinazolinone), 151.28 (C3 quinazolinone), 151.12 (C8a quinazolinone), 143.20 (t, J = 12.9 Hz, C1 aniline), 141.56 (C7 quinazolinone), 129.59 (C5 quinazolinone), 127.72 (C6 quinazolinone), 127.53 (C8 quinazolinone), 120.60 (C4a quinazolinone), 115.12 (dd, J = 22.2, 5.3 Hz, C2,6 anline), 106.24 (t, J = 25.8 Hz, C4 aniline) 26.84 (CH3 acetyl) ppm; HRMS (FAB) calculated for [C16H10ClF2N3O2]+ ([M]+): 349.0430, observed: 349.0426 m/z [M]+.

3.1.9. N-(3,5-Dichlorophenyl)-N-(5-hydroxy-4-oxo-3,4-dihydroquinazolin-2-yl)acetamide (2c)

To a stirred suspension of 5c (100 mg, 0.31 mmol) in CH2Cl2 (2 mL) were added trimethylamine (86 μL, 0.62 mmol) and acetic anhydride (87 μL, 0.93 mmol) at rt. The reaction mixture was stirred for 18 h at 40 °C. The mixture was cooled to rt and diluted with CH2Cl2 (20 mL), then the mixture was washed with water (20 mL). The organic phase was dried over MgSO4 and filtered and concentrated under reduced pressure to obtain a crude compound, which was purified by silica gel column chromatography (Hx/EA 4/1) to produce 2c (64 mg, 57%) as a white solid; mp > 300 °C; 1H NMR (500 MHz, DMSO-d6) δ 13.09 (s, 1H, OH), 11.59 (s, 1H, NH), 7.68 (t, J = 1.9 Hz, 1H, arom.CH), 7.64 (t, J = 8.2 Hz, 1H, arom.CH), 7.60 (s, 2H, arom.CH), 7.03 (d, J = 8.1 Hz, 1H, arom.CH), 6.86 (d, J = 8.2 Hz, 1H, arom.CH), 2.13 (s, 3H, COCH3) ppm; 13C NMR (125 MHz, DMSO-d6) δ 170.72 (C=O acetyl), 166.94 (C=O quinazolinone), 159.69 (C-OH quinazolinone), 148.49 (C2 quinazolinone), 146.77 (C8a quinazolinone), 141.25 (C1 aniline), 136.38 (C7 quinazolinone), 134.31 (C2,6 aniline), 127.96 (C3,5 aniline), 126.89 (C4 aniline), 117.02 (C8 quinazolinone), 112.07 (C6 quinazolinone), 107.07 (C4a quinazolinone), 23.65 (CH3 acetyl) ppm; HRMS (FAB) calculated for [C15H8Cl3N3O2]+ ([M]+): 366.9682, observed: 366.9684 m/z [M]+.

3.1.10. N-(7-Chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-N-(3,5-dichlorophenyl)propionamide (6a)

Following the same procedure used for the synthesis of 2b, 1a (100 mg, 0.29 mmol), trimethylamine (82 μL, 0.59 mmol) and propionyl chloride (55 μL, 0.88 mmol) were used to obtain 6a (61 mg, 52%) as a white solid: mp 223–225 °C; 1H NMR (500 MHz, DMSO-d6) δ 12.87 (s, 1H, NH), 8.09 (d, J = 8.5 Hz, 1H, arom.CH), 7.70 (t, J = 1.9 Hz, 1H, arom.CH), 7.62 (d, J = 2.0 Hz, 1H, arom.CH), 7.59 (d, J = 1.9 Hz, 2H, arom.CH), 7.55 (dd, J = 8.5, 2.1 Hz, 1H, arom.CH), 2.37 (q, J = 7.3 Hz, 2H, CH2), 1.03 (t, J = 7.3 Hz, 3H, CH3) ppm; 13C NMR (125 MHz, DMSO-d6) δ 174.42 (C=O propionyl), 161.49 (C=O quinazolinone), 149.16 (C2 quinazolinone), 148.65 (C8a quinazolinone), 140.91 (C1 aniline), 139.38 (C7 quinazolinone), 134.31 (C2,6 aniline), 128.08 (C5 quinazolinone), 128.06 (C3,5 aniline), 127.22 (C6 quinazolinone), 127.10 (C4 aniline), 126.34 (C8 quinazolinone), 119.69 (C4a quinazolinone), 28.75 (CH2 propionyl), 8.87 (CH3 propionyl) ppm; HRMS (FAB) calculated for [C17H12Cl3N3O2]+ ([M]+): 394.9995, observed: 395.0020 m/z [M]+.

3.1.11. Methyl (7-Chloro-4-oxo-3,4-dihydroquinazolin-2-yl)(3,5-dichlorophenyl)carbamate (6b)

To a stirred suspension of 1a (200 mg, 0.59 mmol) in THF (6 mL) were added trimethylamine (123 μL, 0.88 mmol) and 4-dimethylaminopyridine (7.2 mg, 0.059 mmol) at rt. After stirring for 30 min, methyl chloroformate (68 μL, 0.88 mmol) was added dropwise to the reaction mixture at 0 °C. The resulting solution was stirred for 18 h at rt. After completion of the reaction (measured by TLC), the solution was diluted with ethyl acetate (40 mL), and the mixture was washed with water (20 mL). The organic phase was dried over MgSO4 and filtered and concentrated under reduced pressure to obtain a crude compound, which was purified by silica gel column chromatography (Hx/EA 5/1) to produce 6b (49 mg, 21%) as a white solid; mp 218–220 °C; 1H NMR (400 MHz, DMSO-d6) δ 12.81 (s, 1H, NH), 8.10 (d, J = 8.5 Hz, 1H, arom.CH), 7.60 (t, J = 1.9 Hz, 1H, arom.CH), 7.59 (d, J = 2.1 Hz, 1H, arom.CH), 7.57 (d, J = 1.9 Hz, 2H, arom.CH), 7.53 (dd, J = 8.5, 2.1 Hz, 1H, arom.CH), 3.77 (s, 3H, OCH3) ppm; 13C NMR (100 MHz, DMSO-d6) δ 161.47 (C=O quinazolinone), 153.20 (C2 quinazolinone), 149.10 (C=O methylester), 148.17 (C8a quinazolinone), 141.01 (C7 quinazolinone), 139.34 (C1 aniline), 134.00 (C2,6 aniline), 128.01 (C5 quinazolinone), 127.12 (C3,5 aniline), 127.02 (C6 quinazolinone), 126.14 (C4 aniline), 125.91 (C8 quinazolinone), 119.58 (C4a quinazolinone), 54.30 (CH3 methylester) ppm; HRMS (FAB) calculated for [C16H10Cl3N3O3]+ ([M]+): 396.9788, observed: 396.9777 m/z [M]+.

3.1.12. 7-Chloro-2-((3,5-dichlorophenyl)(methyl)amino)quinazolin-4(3H)-one (6c)

To a stirred suspension of 1a (100 mg, 0.3 mmol) in DMF (2.5 mL) was added sodium hydride (60% dispersion mineral oil, 18 mg, 0.45 mmol) at rt. After stirring for 30 min, iodomethane (22 μL, 0.36 mmol) was added dropwise to the reaction mixture at 0 °C. The resulting mixture was stirred for 2 h at rt. After the completion of the reaction (determined by TLC), the solution was diluted with ethyl acetate (20 mL), and the mixture was washed with water (3 × 10 mL). The organic phase was dried over MgSO4 and filtered and concentrated under reduced pressure to obtain the crude compound, which was purified by silica gel column chromatography (Hx/EA 4/1) to produce 6c (49 mg, 47%) as a white solid; mp 287–289 °C; 1H NMR (500 MHz, DMSO-d6) δ 11.52 (s, 1H, NH), 7.92 (d, J = 8.4 Hz, 1H, arom.CH), 7.63–7.44 (m, 3H, arom.CH), 7.36 (d, J = 2.1 Hz, 1H, arom.CH), 7.22 (dd, J = 8.4, 2.1 Hz, 1H, arom.CH), 3.41 (s, 3H, CH3) ppm; 13C NMR (125 MHz, DMSO-d6) δ 162.54 (C=O quinazolinone), 151.28 (C8a quinazolinone), 146.09 (C1 aniline), 138.91 (C2 quinazolinone), 134.53 (C7 quinazolinone), 128.04 (C5 quinazolinone), 126.02 (C3,5 aniline), 125.51 (C2,6 aniline), 123.93 (C8 quinazolinone), 123.19 (C4a quinazolinone), 116.92 (C4 aniline) ppm; HRMS (FAB) calculated for [C15H10Cl3N3O]+ ([M]+): 352.9889, observed: 352.9879 m/z [M]+.

3.1.13. N-(7-Chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-N-(3,5-dichlorophenyl)-4-methylben-zenesulfonamide (6d)

To a stirred suspension of 1a (100 mg, 0.29 mmol) in CH2Cl2 (3 mL) was added trimethylamine (82 μL, 0.59 mmol) at rt. After stirring for 30 min, p-toluenesulfonyl chloride (168 μL, 0.88 mmol) was added dropwise to the reaction mixture at 0 °C. The resulting solution was stirred for 3 h at 40 °C. After the completion of the reaction (determined by TLC), the mixture was cooled to rt and diluted with CH2Cl2 (20 mL), and then the mixture was washed with water (20 mL). The organic phase was dried over MgSO4 and filtered and concentrated under reduced pressure to obtain a crude compound, which was purified by silica gel column chromatography (Hx/EA 9/1) to produce 6d (116 mg, 80%) as a white solid; mp 163–165 °C; 1H NMR (500 MHz, DMSO-d6) δ 7.96 (d, J = 8.5 Hz, 1H, arom.CH), 7.78 (d, J = 1.9 Hz, 2H, arom.CH), 7.53–7.50 (m, 2H, arom.CH), 7.46 (d, J = 2.0 Hz, 1H, arom.CH), 7.31 (dd, J = 8.5, 2.0 Hz, 1H, arom.CH), 7.27 (t, J = 1.9 Hz, 1H, arom.CH), 7.16–7.13 (m, 2H, arom.CH), 2.29 (s, 3H, CH3) ppm; 13C NMR (125 MHz, DMSO-d6) δ 160.99 (C=O quinazolinone), 148.31 (C2 quinazolinone), 144.84 (C8a quinazolinone), 140.78 (C1 aniline), 139.37 (C7 quinazolinone), 138.30 (C4 tosyl), 134.19 (C1 tosyl), 128.35 (C5 quinazolinone), 128.10 (C3,5 aniline), 125.56 (C2,6 tosyl), 124.18 (C6 quinazolinone), 123.45 (C8 quinazolinone), 122.51 (C4a quinazolinone), 118.55 (C2,6 aniline), 117.21 (C4 aniline), 20.87 (CH3 tosyl) ppm; HRMS (FAB) calculated for [C21H14Cl3N3O3S]+ ([M]+): 492.9821, observed: 492.9840 m/z [M]+.

3.1.14. 2-(Benzyloxy)-N-(7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-N-(3,5-dichlorophenyl)-2-hydroxy-acetamide (7)

To a stirred suspension of 1a (3 g, 8.8 mmol) in CH2Cl2 (50 mL) was added trimethylamine (2.5 mL, 17.6 mmol) at rt. After stirring for 30 min, benzyloxyacetyl chloride (4.4 mL, 26.4 mmol) was added dropwise to the reaction mixture at 0 °C. The resulting solution was stirred for 3 h at 40 °C. After the completion of the reaction (determined by TLC), the mixture was washed and cooled to rt and diluted with CH2Cl2 (100 mL). The mixture was then washed with water (100 mL). The organic phase was dried over MgSO4 and filtered and concentrated under reduced pressure to obtain a crude compound, which was purified by silica gel column chromatography (Hx/EA 5/1) to produce 7 (4.2 g, 98%) as a colorless oil; mp 282–284 °C; 1H NMR (300 MHz, acetone-d6) δ 12.15 (s, 1H, NH), 8.11 (d, J = 8.5 Hz, 1H, arom.CH), 7.65 (d, J = 1.3 Hz, 3H, arom.CH), 7.46 (dd, J = 8.5, 2.1 Hz, 1H, arom.CH), 7.40 (d, J = 2.0 Hz, 1H, arom.CH), 7.33–7.25 (m, 5H, arom.CH), 4.58 (s, 2H, CH2), 4.32 (s, 2H, CH2) ppm; 13C NMR (125 MHz, acetone-d6) δ 173.77 (C=O acetamide), 161.17 (C=O quinazolinone), 150.19 (C2 quinazolinone), 149.82 (C8a quinazolinone), 140.87 (C7 quinazolinone), 140.11 (C1 benzyloxy), 138.56 (C2,6 aniline), 135.91 (C5 quinazolinone), 129.85 (C6 quinazolinone), 129.08 (d, J = 3.7 Hz, C3,5 benzyloxy), 128.71 (t, J = 23.6 Hz, C4 aniline), 127.13 (d, J = 10.0 Hz, C8 quinazolinone), 120.20 (C4a quinazolinone), 73.73 (CH2 benzyloxy), 70.59 (CH2 acetamide) ppm; HRMS (FAB) calculated for [C23H16Cl3N3O3]+ ([M]+): 487.0257, observed: 487.0260 m/z [M]+.

3.1.15. N-(7-Chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-N-(3,5-dichlorophenyl)-2-hydroxy-acetamide (8)

To a stirred solution of 7 (3 g, 6.1 mmol) in ethyl acetate (70 mL) was added 10% palladium on activated carbon (1.2 g) at rt. The reaction mixture was stirred under H2 for 2 h at rt. After the completion of the reaction (determined by TLC), the mixture was diluted with CH2Cl2 (200 mL) and methanol (200 mL), and the suspension was then filtered through a celite pad and concentrated to produce alcohol 8 (194 mg, 8%) as a white solid; mp 263–265 °C; 1H NMR (500 MHz, DMSO-d6) δ 12.73 (s, 1H, OH), 10.59 (s, 1H, NH), 8.01 (d, J = 8.5 Hz, 1H, arom.CH), 7.66 (d, J = 1.9 Hz, 2H, arom.CH), 7.43 (d, J = 2.1 Hz, 1H, arom.CH), 7.38 (dd, J = 8.5, 2.0 Hz, 1H, arom.CH), 7.31 (t, J = 2.0 Hz, 1H, arom.CH), 5.05 (s, 2H, CH2) ppm; 13C NMR (125 MHz, DMSO-d6) δ 166.19 (C=O hydroxy acetamide), 161.95 (C=O quinazolinone), 154.21 (C2 quinazolinone), 149.28 (C8a quinazolinone), 140.77 (C1 aniline), 139.30 (C7 quinazolinone), 134.26 (C2,6 aniline), 134.08 (C5 quinazolinone), 128.26 (C6 quinazolinone), 124.87 (d, J = 20.9 Hz, C3,5 aniline), 122.94 (C4 aniline), 118.22 (C8 quinazolinone), 117.43 (C4a quinazolinone), 64.91 (CH2 hydroxyacetamide) ppm; HRMS (FAB) calculated for [C16H10Cl3N3O3]+ ([M]+): 396.9788, observed: 396.9767 m/z [M]+.

3.2. Cell Line and Virus

Vero cells (ATCC CCL-81, Manassas, VA, USA) were maintained at 37 °C with 5% CO2 in Dulbecco’s Modified Eagle’s medium (DMEM; Welgene, Gyeongsan-si, Korea) supplemented with 10% heat-inactivated fetal bovine serum (FBS) and 1X antibiotic-antimycotic solution (Gibco/Thermo Fisher Scientific, Waltham, MA, USA). SARS-CoV-2 (βCoV/KOR/KCDC03/2020) was supplied by the Korea Centers for Disease Control and Prevention (KCDC). This virus was propagated in Vero cells, and viral titers were determined by plaque assays in the Vero cells. All experiments related to SARS-CoV-2 were conducted at laboratories of the Institut Pasteur Korea in accordance with the guidelines of the Korea National Institute of Health (KNIH) using enhanced Biosafety Level 3 (BSL-3) containment procedures approved for use by the KCDC [25].

3.3. Concentration–Response Curve Analysis by Immunofluorescence Assay

Vero cells were seeded at 1.2 × 104 cells in 384-well, μClear plates (Greiner Bio-One, Kremsmünster, Austria) 24 h prior to the experiment. Compounds were placed in intermediate 384-well plates containing serum-free media (Gibco, Waltham, MA, USA). The diluted compounds (10 concentrations, 0.05–25 μM) were added to the cell plates in 10 μL volumes (at a final DMSO concentration of 0.5% (v/v)). For viral infection, plates were moved into the BSL-3 containment facility, and SARS-CoV-2 was added to the Vero cells at a multiplicity of infection (MOI) of 0.0125. At 24 h post-infection, the cells were fixed with 4% paraformaldehyde and stained with SARS-CoV-2 nucleocapsid protein, and immunofluorescence analysis was performed. To quantify the number of cells and infection ratios, Columbus software (PerkinElmer, Waltham, MA, USA) was used, and antiviral activity was normalized to the positive (mock-infected) and negative (0.5% DMSO) controls in each assay plate. Concentration–response curves were fitted by sigmoidal models using XLfit 4 in Microsoft Excel or GraphPad Prism 6.0 software (GraphPad Software, San Diego, CA, USA). The IC50 values were calculated from curves fitted to the normalized activity dataset. The quality of each assay was controlled by the Z′-factor [25].

3.4. Pseudovirus-Based Entry Assay

For the SARS-CoV-2 pseudovirus entry assay, H1299 (human lung squamous carcinoma cell) cells stably expressing ACE2 and TMPRSS2 were seeded in white, 384-well, μClear plates (Greiner Bio-One) so that they reached 70% confluency the following day. The cells were pre-treated with serially diluted compounds and mixed with SARS-CoV-2 pseudovirus particles. After incubation for 24 h, the culture medium was replaced with fresh DMEM containing 2% FBS. Pseudovirus entry efficiency was quantified by measuring luciferase activity in infected cells 48 h after infection using a Bright-Glo luciferase assay system (Promega, Madison, WI, USA). The relative luminescence units were normalized to the positive (0.5% DMSO, set as 100%) and negative (mock-infected, set as 0%) controls, and the IC50 values were calculated using GraphPad Prism 6.0 software. Cell viability was measured using a CellTiter-Glo luminescent cell viability assay (Promega, Madison, WI, USA) according to the manufacturer’s instructions [26].

3.5. hERG Channel Patch-Clamp Assay

hERG-HEK293 cells (Genionics, Zürich, Switzerland) were cultured in DMEM/F-12 medium (10% FBS, 7.5 mg/mL, blasticidin S HCl, 50 mg/mL hygromycin B). Cells (2 × 105) were seeded in a 60 mm cell-culture dish. After culturing for 2 days in an incubator at 5% CO2 and 37 °C, the prepared cells and Sealchips (Aviva Biosciences, San Diego, CA, USA) were loaded into a PatchXpress 7000A (Molecular Devices, San Jose, CA, USA) patch-clamp system, and a protocol for measuring hERG channel activity was conducted. A pressure of −35 to −47 mmHg was applied to position the cells in the micro-holes of the Sealchip. A negative pressure of 0 to −45 mmHg was repeatedly applied until a seal resistance of 1 GΩ was obtained, and a negative pressure of −130 mmHg was applied to form a whole-cell patch. A MultiClamp 700A microelectrode amplifier was used for voltage-clamping and data acquisition, and DataXpress software 2.0.4.5 (Molecular Devices) was used to measure the tail current amplitude to determine hERG channel activity. Data were analyzed using Clampfit 9.2 software (Molecular Devices).

3.6. Microsomal Stability Assay

The phase I stability of the compounds was measured by quantifying (using LC/MS/MS) the amount of compound remaining after exposure to liver microsomes in which the metabolic enzyme system was activated by NADPH for 30 min. The activity of the enzyme system was confirmed using buspirone as a reference compound (<10% of buspirone remained in human microsomes, <5% of buspirone remained in rat microsomes) [29].

3.7. Cell Viability Assay

An EZ-Cytox assay (DoGenBio, Seoul, Korea) was used to determine cell viability. Cells (2 × 104 cells) were seeded in a 96-well plate and cultured in RPM1640 supplemented with 10% FBS in a 5% CO2 incubator at 37 °C. After 24 h, 100, 10, 1, 0.1, and 0.01 μM of each compound was added to the wells. After 24 h, 10 μL of the WST reagent solution was added to each well. After incubation for 3 h, absorbance was measured at 450 nm using a microplate reader. Cell viability was determined as the percentage of the measured value in the presence of compound compared with the DMSO control, and the CC50 value was obtained from the cell viability plot in GraphPad prism 6 [28].

4. Conclusions

To improve the in vivo pharmacokinetics of 2-aminoquinazolin-4-(3H)-one compounds, we synthesized a series of N-substituted derivatives. These compounds could be conveniently prepared on a large scale through a one-pot reaction using Dimroth rearrangement as a key step. All of the N-acetylated compounds showed good potency and favorable properties such as low hERG binding and good microsomal stability. The results of the pharmacokinetic studies in rats showed that compound 2b had the highest AUC24h (41.57 μg∙h/mL), and the blood concentration sufficiently exceeded the IC50 value within at least 8 h. Furthermore, the in vivo toxicity of compound 2b was assessed over 15 days following a single dose of either 250 or 500 mg/kg. The results showed that no animals died and that the approximate lethal dose is likely more than 500 mg/kg. Consequently, this study shows that compound 2b is a very promising lead compound for developing anti-SARS-CoV-2 agents.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ph15070831/s1, NMR spectra of synthesized compounds.

Author Contributions

Conceptualization, Y.S.S., J.Y.L. and C.M.P.; validation, H.R.K., H.-g.P., L.S.J. and C.M.P.; formal analysis, Y.S.S. and J.Y.L.; organic synthesis, Y.S.S., J.Y.L., J.-E.C., S.M. and J.H.S.; biological Evaluation, S.J., S.K. and M.S.J.; data curation, Y.S.S., J.Y.L., S.K., M.S.J. and H.R.K.; writing—original draft preparation, Y.S.S. and J.Y.L.; writing—review and editing, H.-g.P., L.S.J. and C.M.P.; supervision, C.M.P.; funding acquisition: H.R.K. and C.M.P. All authors have read and agreed to the published version of the manuscript.

Funding

This research was supported through the National Research Council of Science & Technology (NST) (No. CRC-16-01-KRICT) funded by the Ministry of Science and ICT (MSIP).

Institutional Review Board Statement

This study was approved by the Institutional Animal Care and Use Committee of KIT (approval number, KIT-N121020).

Informed Consent Statement

Not applicable.

Data Availability Statement

The data presented in this study are available in the article.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Cui, J.; Li, F.; Shi, Z.-L. Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol. 2019, 17, 181–192. [Google Scholar] [CrossRef] [Green Version]
  2. Li, G.; De Clercq, E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat. Rev. Drug Discov. 2020, 19, 149–150. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Gil, C.; Ginex, T.; Maestro, I.; Nozal, V.; Barrado-Gil, L.; Cuesta-Geijo, M.; Urquiza, J.; Ramírez, D.; Alonso, C.; Campillo, N.E.; et al. COVID-19: Drug Targets and Potential Treatments. J. Med. Chem. 2020, 63, 12359–12386. [Google Scholar] [CrossRef] [PubMed]
  4. World Health Organization (WHO). Weekly Operational Update on COVID-19. Available online: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19 (accessed on 15 June 2022).
  5. Liu, D.X.; Liang, J.Q.; Fung, T.S. Human coronavirus-229E, -OC43, -NL63, and -HKU1 (Coronaviridae). In Encyclopedia of Virology; Academic Press: Cambridge, MA, USA, 2021; pp. 428–440. [Google Scholar]
  6. Lu, R.; Zhao, X.; Li, J.; Niu, P.; Yang, B.; Wu, H.; Wang, W.; Song, H.; Huang, B.; Zhu, N.; et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet 2020, 395, 565–574. [Google Scholar] [CrossRef] [Green Version]
  7. Olivera, T.; Karim, S.A. New SARS-CoV-2 Variants—Clinical, Public Health, and Vaccine Implications. N. Engl. J. Med. 2021, 384, 1866–1868. [Google Scholar]
  8. Mahase, E. Delta variant: What is happening with transmission, hospital admissions, and restrictions. BMJ 2021, 373, n1513. [Google Scholar] [CrossRef]
  9. Mahase, E. Covid-19: Hospital admission 50–70% less likely with omicron than delta, but transmission a major concern. BMJ 2021, 375, n3151. [Google Scholar] [CrossRef]
  10. Gatti, M.; De Ponti, F. Drug Repurposing in the COVID-19 Era: Insights from Case Studies Showing Pharmaceutical Peculiarities. Pharmaceutics 2021, 13, 302. [Google Scholar] [CrossRef]
  11. The RECOVERY Collaborative Group. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N. Engl. J. Med. 2020, 383, 2030–2040. [Google Scholar] [CrossRef]
  12. Horby, P.W.; Mafham, M.; Bell, J.L.; Linsell, L.; Staplin, N.; Emberson, J.; Palfreeman, A.; Raw, J.; Elmahi, E.; Prudon, B.; et al. Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. Lancet 2020, 396, 1345–1352. [Google Scholar] [CrossRef]
  13. Beigel, J.H.; Tomashek, K.M.; Dodd, L.E.; Mehta, A.K.; Zingman, B.S.; Kalil, A.C.; Hohmann, E.; Chu, H.Y.; Luetkemeyer, A.; Kline, S.; et al. Remdesivir for the Treatment of Covid-19—Final Report. N. Engl. J. Med. 2020, 383, 1813–1826. [Google Scholar] [CrossRef] [PubMed]
  14. Jayk Bernal, A.; Gomes da Silva, M.M.; Musungaie, D.B.; Kovalchuk, E.; Gonzalez, A.; Delos Reyes, V.; Martín-Quirós, A.; Caraco, Y.; Williams-Diaz, A.; Brown, M.L.; et al. Molnupiravir for Oral Treatment of COVID-19 in Nonhospitalized Patients. N. Engl. J. Med. 2022, 386, 509–520. [Google Scholar] [CrossRef] [PubMed]
  15. Whitley, R. Molnupiravir—A Step toward Orally Bioavailable Therapies for Covid-19. N. Engl. J. Med. 2021, 386, 592–593. [Google Scholar] [CrossRef] [PubMed]
  16. Painter, G.R.; Natchus, M.G.; Cohen, O.; Holman, W.; Painter, W.P. Developing a direct acting, orally available antiviral agent in a pandemic: The evolution of molnupiravir as a potential treatment for COVID-19. Curr. Opin. Virol. 2021, 50, 17–22. [Google Scholar] [CrossRef] [PubMed]
  17. Fischer, W.A.; Eron, J.J.; Holman, W.; Cohen, M.S.; Fang, L.; Szewczyk, L.J.; Sheahan, T.P.; Baric, R.; Mollan, K.R.; Wolfe, C.R.; et al. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. Sci. Transl. Med. 2022, 14, 1–11. [Google Scholar] [CrossRef]
  18. Gordon, C.J.; Tchesnokov, E.P.; Schinazi, R.F.; Götte, M. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. J. Biol. Chem. 2021, 297, 100770. [Google Scholar] [CrossRef]
  19. Janion, C. On the different response of Salmonella Typhimurium HISG46 and TA1530 to mutagenic acion of base analogues. Acta Biochim. Pol. 1979, 26, 171–177. [Google Scholar]
  20. Press Release Archive in Pfizer. Available online: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-additional-phase-23-study-results (accessed on 1 April 2022).
  21. Lee, J.Y.; Shin, Y.S.; Jeon, S.; Lee, S.I.; Noh, S.; Cho, J.E.; Jang, M.S.; Kim, S.; Song, J.H.; Kim, H.R.; et al. Design, synthesis and biological evaluation of 2-aminoquinazolin-4(3H)-one derivatives as potential SARS-CoV-2 and MERS-CoV treatments. Bioorg. Med. Chem. Lett. 2021, 39, 127885. [Google Scholar] [CrossRef]
  22. Lee, J.Y.; Shin, Y.S.; Jeon, S.; Lee, S.I.; Cho, J.; Myung, S.; Jang, M.S.; Kim, S.; Song, J.H.; Kim, H.R.; et al. Synthesis and biological evaluation of 2-benzylaminoquinazolin-4(3H)-one derivatives as a potential treatment for SARS-CoV-2. Bull. Korea Chem. Soc. 2022, 43, 412–416. [Google Scholar] [CrossRef]
  23. Liao, Z.Y.; Yeh, W.H.; Liao, P.Y.; Liu, Y.T.; Chen, Y.C.; Chen, Y.H.; Hsieh, T.H.; Lin, C.C.; Lu, M.H.; Chen, Y.S.; et al. Regioselective synthesis and biological evaluation of: N -substituted 2-aminoquinazolin-4-ones. Org. Biomol. Chem. 2018, 16, 4482–4494. [Google Scholar] [CrossRef]
  24. Boyle, P.H.; Lockhart, R.J. Synthesis and properties of 7-alkoxyfurazano[3,4-d]pyrimidines and their use in the preparation of 4-alkoxypteridines and N3-substituted pterins. J. Org. Chem. 1985, 50, 5127–5132. [Google Scholar] [CrossRef]
  25. Shin, Y.S.; Lee, J.Y.; Noh, S.; Kwak, Y.; Jeon, S.; Kwon, S.; Jin, Y.-H.; Jang, M.S.; Kim, S.; Song, J.H.; et al. Discovery of cyclic sulfonamide derivatives as potent inhibitors of SARS-CoV-2. Bioorg. Med. Chem. Lett. 2021, 31, 127667. [Google Scholar] [CrossRef] [PubMed]
  26. Kim, T.Y.; Jeon, S.; Jang, Y.; Gotina, L.; Won, J.; Ju, Y.H.; Kim, S.; Jang, M.W.; Won, W.; Park, M.G.; et al. Platycodin D, a natural component of Platycodon grandiflorum, prevents both lysosome- and TMPRSS2-driven SARS-CoV-2 infection by hindering membrane fusion. Exp. Mol. Med. 2021, 53, 956–972. [Google Scholar] [CrossRef] [PubMed]
  27. El-Haj, B.M.; Ahmed, S.B.M.; Garawi, M.A.; Ali, H.S. Linking aromatic hydroxy metabolic functionalization of drug molecules to structure and pharmacologic activity. Molecules 2018, 23, 2119. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  28. Huang, Z.; Lee, H.; Lee, E.; Kang, S.K.; Nam, J.M.; Lee, M. Responsive nematic gels from the self-assembly of aqueous nanofibres. Nat. Commun. 2011, 2, 6–10. [Google Scholar] [CrossRef]
  29. Di, L.; Kerns, E.H.; Hong, Y.; Kleintop, T.A.; McConnell, O.J.; Huryn, D.M. Optimization of a higher throughput microsomal stability screening assay for profiling drug discovery candidates. J. Biomol. Screen. 2003, 8, 453–462. [Google Scholar] [CrossRef] [Green Version]
Pharmaceuticals 15 00831 g001 550
Figure 1. Design of novel 2-aminoquinazolinone compounds to improve in vivo pharmacokinetics.
Figure 1. Design of novel 2-aminoquinazolinone compounds to improve in vivo pharmacokinetics.
Pharmaceuticals 15 00831 g001
Pharmaceuticals 15 00831 sch001 550
Scheme 1. Synthesis of 2-aminoquinazolin-4-(3H)-one derivatives. Reagents and conditions: (a) (i) Compound 4a or 4b, TMSCl, t-BuOH, 60 °C, 4 h; (ii) 2 N NaOH in EtOH/H2O (v/v, 1/1), reflux, 6 h; (b) BBr3, DCM, −78 °C to rt, 3 h; (c) acetic anhydride, TEA, DCM, 40 °C; (d) propionyl chloride or methyl chloroformate or iodomethane or p-TsCl, TEA, DCM, 40 °C; (e) benzyloxyacetyl chloride, TEA, DCM, 40 °C, 3 h; (f) Pd/C, H2, ethyl acetate, rt, 2 h.
Scheme 1. Synthesis of 2-aminoquinazolin-4-(3H)-one derivatives. Reagents and conditions: (a) (i) Compound 4a or 4b, TMSCl, t-BuOH, 60 °C, 4 h; (ii) 2 N NaOH in EtOH/H2O (v/v, 1/1), reflux, 6 h; (b) BBr3, DCM, −78 °C to rt, 3 h; (c) acetic anhydride, TEA, DCM, 40 °C; (d) propionyl chloride or methyl chloroformate or iodomethane or p-TsCl, TEA, DCM, 40 °C; (e) benzyloxyacetyl chloride, TEA, DCM, 40 °C, 3 h; (f) Pd/C, H2, ethyl acetate, rt, 2 h.
Pharmaceuticals 15 00831 sch001
Pharmaceuticals 15 00831 g002 550
Figure 2. Pharmacokinetic evaluation of compounds 1a, 2a, 2b, and 2c. Each compound was orally administrated to male Sprague Dawley rats (n = 3) at 10 mg/kg.
Figure 2. Pharmacokinetic evaluation of compounds 1a, 2a, 2b, and 2c. Each compound was orally administrated to male Sprague Dawley rats (n = 3) at 10 mg/kg.
Pharmaceuticals 15 00831 g002
Pharmaceuticals 15 00831 g003 550
Figure 3. Body weight changes in male rats (n = 4) treated with compound 2b in a single-dose toxicity study. ** p < 0.01, compared to the control at the same time point (Dunnett’s test).
Figure 3. Body weight changes in male rats (n = 4) treated with compound 2b in a single-dose toxicity study. ** p < 0.01, compared to the control at the same time point (Dunnett’s test).
Pharmaceuticals 15 00831 g003
Table
Table 1. The anti-SARS-CoV-2 activity and ClogP values of 2-aminoquinazolin-4(3H)-one derivatives.
Table 1. The anti-SARS-CoV-2 activity and ClogP values of 2-aminoquinazolin-4(3H)-one derivatives.
Pharmaceuticals 15 00831 i001
CompoundRXYIC50 a (μM)CC50 b (μM)SI cClogP d
1aH7-ClCl0.23>251105.0
1bH7-ClF0.2418743.9
2a-COCH37-ClCl0.339.39262.4
2b-COCH37-ClF0.29>25871.3
2c-COCH35-OHCl0.11>252271.8
5cH5-OHCl0.15>251684.5
6a-COCH2CH37-ClCl0.21>251175.1
6b-CO2CH37-ClCl7.05>2545.1
6c-CH37-ClCl5.66>2544.8
6dp-Ts7-ClCl0.57>25446.5
8-COCH2OH7-ClCl2.57>25103.8
Remdesivir 3.47>50143.2
a,b IC50 and CC50 values were derived from the results of at least two independent experiments conducted in Vero cells. c SI (selectivity index) = CC50/IC50 value for inhibiting SARS-CoV-2 infection. d ClogP values were calculated using ChemDraw Ultra, version 19.0.
Table
Table 2. hERG, microsomal stability, and cytotoxicity of N-acetylated compounds.
Table 2. hERG, microsomal stability, and cytotoxicity of N-acetylated compounds.
CompoundhERG
K+ Channel IC50 (μM)		Microsomal
Stability (%) a		Cytotoxicity (μM) b
RatHumanHFL-1L929NIH 3T3CHO-K1
2a15.278832.21.27.61.5
2b30.0>99>9912.617.922.714.6
2c>50571013.742.759.917.1
a The percentage of the original compound remaining after 30 min incubation. b Cytotoxicity was tested in four cell lines; HFL-1, human embryonic lung cells; L929, NCTC clone 929 mouse fibroblast cells; NIH 3T3, mouse embryonic fibroblast cells; CHO-K1, Chinese hamster ovary cells.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Shin, Y.S.; Lee, J.Y.; Jeon, S.; Cho, J.-E.; Myung, S.; Jang, M.S.; Kim, S.; Song, J.H.; Kim, H.R.; Park, H.-g.; et al. Optimization of 2-Aminoquinazolin-4-(3H)-one Derivatives as Potent Inhibitors of SARS-CoV-2: Improved Synthesis and Pharmacokinetic Properties. Pharmaceuticals 2022, 15, 831. https://doi.org/10.3390/ph15070831

AMA Style

Shin YS, Lee JY, Jeon S, Cho J-E, Myung S, Jang MS, Kim S, Song JH, Kim HR, Park H-g, et al. Optimization of 2-Aminoquinazolin-4-(3H)-one Derivatives as Potent Inhibitors of SARS-CoV-2: Improved Synthesis and Pharmacokinetic Properties. Pharmaceuticals. 2022; 15(7):831. https://doi.org/10.3390/ph15070831

Chicago/Turabian Style

Shin, Young Sup, Jun Young Lee, Sangeun Jeon, Jung-Eun Cho, Subeen Myung, Min Seong Jang, Seungtaek Kim, Jong Hwan Song, Hyoung Rae Kim, Hyeung-geun Park, and et al. 2022. "Optimization of 2-Aminoquinazolin-4-(3H)-one Derivatives as Potent Inhibitors of SARS-CoV-2: Improved Synthesis and Pharmacokinetic Properties" Pharmaceuticals 15, no. 7: 831. https://doi.org/10.3390/ph15070831

APA Style

Shin, Y. S., Lee, J. Y., Jeon, S., Cho, J. -E., Myung, S., Jang, M. S., Kim, S., Song, J. H., Kim, H. R., Park, H. -g., Jeong, L. S., & Park, C. M. (2022). Optimization of 2-Aminoquinazolin-4-(3H)-one Derivatives as Potent Inhibitors of SARS-CoV-2: Improved Synthesis and Pharmacokinetic Properties. Pharmaceuticals, 15(7), 831. https://doi.org/10.3390/ph15070831

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop